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Abstract
Background: This study investigates the protective effects of turmeric (Curcuma longa, CL) on acetic acid-induced
colitis in rats.
Method: Inflammatory bowel disease (IBD) was induced in male Wistar rats by intra-rectal administration of 1 ml of
4 % acetic acid at 8 cm proximal to the anus for 30 s. Curcuma longa (CL) powder, (1, 10, or 100 mg/kg/day) was
administered for either 3 days before or after IBD for 7 days. The body weight, macroscopic and microscopic
analysis of the colon of CL-treated IBD rats and that of control rats (no IBD, no CL) were performed on 0 day, 2, 4
and 7th day. Myeloperoxidase (MPO), IL-23 and glutathione levels in control, untreated and treated rats were
measured by ELISA.
Results: CL significantly (P < 0.05) improved IBD-induced reduction in mean body weight and mean macroscopic
ulcer score. Administration of CL also significantly (P < 0.01) reduced the mean microscopic ulcer score when
compared to untreated IBD control. Intake of CL by rats resulted in a significant (P < 0.05) increase in the mean
serum glutathione level compared to untreated control. CL reduced both MPO and IL-23 levels in the colonic
mucosa of the rat.
Conclusion: CL improved body weight gain, mean macroscopic and microscopic ulcer scores in the colon of rats
suffering from acetic acid-induced IBD. CL reduced both MPO and IL-23 in the mucosa of the colon. The increase in
the mean serum glutathione level may help in the reduction of oxidative stress associated with IBD.
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Background
Inflammatory bowel disease (IBD) is characterized by
recurrent ulceration of the bowel and is of unknown
etiology [1]. The pathogenesis likely involves genetic,
environmental, and immunologic factors [2, 3]. Genetic
deletion or antibody-mediated neutralization of inter-
leukin 12 (IL-12) led to amelioration of intestinal in-
flammation in a number of different models [4, 5].
The discovery in 2000 of a related cytokine interleukin
(IL) 23, has, however, led to the re-evaluation of the func-
tional role of IL-12 in inflammation. In fact, it was shown
that IL-23 and not IL-12 is the key molecule in the devel-
opment of a variety of inflammatory conditions including
intestinal inflammation [6]. The demonstration of the as-
sociation of genetics in the IL-23 pathway in multiple
chronic inflammatory disorders, including inflamma-
tory bowel disease (IBD), has coincided with signifi-
cant advances in the understanding of its key role in
host defense and organ-specific autoimmunity. Evi-
dence for the importance of IL-23 pathway in IBD
has come from mouse models of IBD, in which IL-23
deficiency or blockade protects not only the mice from
the disease [7, 8], but human IBD as well [9–11].
* Correspondence: sbastaki@uaeu.ac.ae; eadeghate@uaeu.ac.ae
1Department of Pharmacology, College of Medicine and Health Sciences,
United Arab Emirates University, P.O. Box 17666 Al Ain, UAE
2Department of Anatomy, College of Medicine and Health Sciences, United
Arab Emirates University, P.O. Box 17666 Al Ain, UAE
© 2016 Bastaki et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bastaki et al. BMC Complementary and Alternative Medicine  (2016) 16:72 
DOI 10.1186/s12906-016-1057-5
Treating IBD and limiting drug toxicity is a continu-
ous challenge. The drugs of choice for the treatment of
IBD are 5-aminosalicylic acid and sulfasalazine. Others
include corticosteroids, azathioprine, mercaptopurines
and cyclosporine, which are used for more severe forms
of the disease [12]. There is a pressing need for developing
new and effective therapeutic approaches with limited tox-
icity. The use of medicinal plants or their active compo-
nents is becoming an increasingly attractive approach for
the treatment of various inflammatory disorders among
patients unresponsive to steroids or unwilling to take
standard medications. Food derivatives are increasingly
being used as therapy for IBD because of limited toxicity.
During the last ten years, a large number of dietary com-
ponents have been evaluated as potential chemo-
preventive agents [13]. Turmeric, the powdered rhizome
of the medicinal plant, Curcuma longa Linn, of the Zingi-
beraceae family is widely used as a food flavouring and
colouring agent in the Asian cuisine. It grows naturally
throughout the Indian subcontinent and in tropical cli-
mates. India produces most of the world’s turmeric [14,
15]. Its yellow colour is due to curcumin (diferuloyl-
methane), a polyphenolic pigment [16]. Curcumin has
been used since ancient times for its medicinal property in
India and Southeast Asia and is known to possess a variety
of pharmacological effects including anti-inflammatory ac-
tivities. Studies by Chuang et al. showed that curcumin,
the active ingredient of turmeric strongly inhibited drug-
induced inflammation in the liver [17]. It was also shown
that curcumin was able to inhibit NF-Kappa B, the mol-
ecule responsible for the proliferation of inflammatory cyto-
kines in colitis [18]. In this particular study, curcumin made
up 2.0 % of the daily feed of the Wistar rats for a period of
two weeks [18]. Mucosal damage was also reported to be
improved in colitis induced by trinitrobenzene sulphonic
acid [19]. Extract of the turmeric has also been reported to
have myorelaxant effect in addition to anti-inflammatory
action on animal models of colitis [20]. Since turmeric is
widely used as a flavouring agent in food and because of its
medicinal properties, it was thought worthwhile to investi-
gate the protective effects of turmeric (Curcuma longa, CL)
on acetic acid-induced colitis in a rat model of IBD with
special emphasis on colon ulcers and lymphatic infiltration.
Methods
Animals
Male Wistar rats weighing between 225–240 g were
used for the experiments. Rats were housed under nor-
mal laboratory conditions set at 21–24 °C and 40–60 %
relative humidity, under 12 h light/dark cycle with free
access to standard rodent food and water. For each set
of experiments, the animals were divided into three
groups, control (no IBD, no CL); untreated (IBD, no CL);
treated (IBD, CL). The experimental protocols of this
study were approved by the Institutional Animals Ethical
Committee of the United Arab Emirates University
(Ethical Approval # A6-15). All experiments were per-
formed according to ethical guidelines set by the United
Arab Emirates University.
Induction of colitis
After an overnight fasting, the rats were lightly anaesthe-
tized with ether and IBD was induced by intrarectal ad-
ministration of 1 ml of 4 % acetic acid at 8 cm proximal
to the anus for 30 s. To flush the colon, 1 ml of phos-
phate buffered saline (PBS) was similarly administered.
Pharmacological treatment
CL powder (1, 10, or 100 mg/kg/day), purchased from
Mehran Spice & Food Industries, Plot # 14 & 15 Sector
24, Korangi Industrial Area, Karachi, Pakistan, was admin-
istered orally for 3 days before or 30 min after the induc-
tion of IBD. Control animals received 1 ml/kg saline using
the same technique. The animals were weighed at 0 day,
2, 4 and 7 days after IBD in both control (no IBD nor CL
treatment) and in CL-treated IBD rats.
Macroscopic evaluation of colonic damage
To examine the extent of colonic inflammation by macro-
scopic and microscopic analysis, histological samples were
collected at selected time points (0 day, after 3 days of
treatment and after 2, 4 and 7 days of IBD with or without
CL treatment). Briefly, immediately after the 7th day of
IBD, the rats were euthanized by cervical dislocation and
the colon excised 8 cm above the anal margin, opened
longitudinally and washed with saline. Macroscopic dam-
age was assessed by the scoring system of Wallace and
Keenan [21], which takes into account the area of inflam-
mation and the presence or absence of ulcers. Briefly, the
criteria for assessing macroscopic damage was based on a
semi quantitative scoring system where features are
graded as follows: 0, no ulcer, no inflammation; 1, no
ulcer, local hyperaemia; 2, ulceration without hyperaemia;
3, ulceration and inflammation at one site only; 4, two or
more sites of ulceration and inflammation; 5, ulceration
extending more than 2 cm.
Histology
After macroscopic observation, samples of the colon
were subsequently excised for microscopic observation.
Microscopic analysis was based on the scoring system of
Neurath et al., [5]. The colon was fixed in 10 % formalin
in phosphate buffered saline (PBS) for 1 week after
which it was washed under running tap water for 2 h.
The samples were then dehydrated in graded ethanol
and then embedded in paraffin wax. Thereafter, the
sections were deparaffinized with xylene, stained with
haematoxylin-eosin and were viewed microscopically.
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Lymphatic infiltration was scored as follows: none;
confined to the mucosa; mucosa and submucosa; tra-
verses the whole length of the colonic wall.
Determination of myeloperoxidase
Myeloperoxidase (MPO) was measured by sandwich
ELISA according to manufacturer’s protocols. Briefly,
100 μl of the sample and standards were added to the 96
well microtiter plate, coated with antibodies recognizing
rat MPO, for 1 h at room temperature. After washing,
100 μl /well biotinylated trace antibody was added for 1 h
at room temperature. After washing, Streptavidin-
peroxidase conjugate was added to bind with biotinylated
trace antibody for 1 h at room temperature. The
TMB-ELISA substrate was added for 30 min at room
temperature, after washing of the plate. The enzyme
reaction was stopped by oxalic acid. The absorbance was
read at 450 nm, after adding stop solution, with a mi-
croplate reader (Tecan Group Ltd., Männedorf,
Switzerland). MPO levels were expressed as ng per
milligram of protein.
Determination of IL −23
Enzyme immunoassay of IL-23, in distal colon protein
samples was performed by using commercial Six C USA
sandwich ELISA kit. Briefly, sample and standards were
added to the coated 96 well micro titer plate for 30 min
at 37 °C. After washing, HRP was added for at 37 °C.
The TMB-ELISA substrate was added, after washing.
The absorbance was read at 450 nm, after adding a stop
solution, with a microplate reader (Tecan Group Ltd.,
Männedorf, Switzerland). IL −23 levels were expressed
as pg per milligram of protein.
Determination of glutathione
Enzyme immunoassay of glutathione (GSH) in serum
was performed by using Six C USA Sandwich ELISA kit.
Briefly, sample and standards were added to the coated
96 well micro titer plate for 30 min at 37 °C. The
procedure was performed according to the guidelines
given by the vendor (Tecan Group Ltd., Männedorf,
Switzerland). Serum GSH levels were expressed as μM per
litre of blood.
Protein extraction for ELISA
Samples of 8 cm portion of distal colon were cut longi-
tudinally to open, washed with ice-cold PBS, and the
mucosa was rapidly scraped from the underlying tissue
layers on ice. The mucosa was weighed, minced by for-
ceps, and homogenized with 10 volumes of in ice-cold
high KCl lysis buffer 10 mM Tris–HCl, pH 8.0, 140 mM
NaCl, 300 mM KCl, 1 mM EDTA, 0.5 % Triton X-100
and 0.5 % sodium deoxycholate with complete protease
inhibitor cocktail with a polytron homogenizer (IKA
laboratory, Germany). The resulting homogenates, after
30 min incubation on ice, were centrifuged at 15000 rpm
for 30 min at 4 °C. The resulting supernatant was stored
at −80 °C until the ELISA was performed. Protein concen-
tration was determined in each sample by the BCA
method based commercial kit.
Chemicals and kits
Acetic acid was purchased from BDH Prolabo (10
Village Crescent, Linbro Business Park, Linbro Park,
2065, Johannesburg, South Africa). Sodium deoxycholate
and all other chemicals, if not specified were purchased
from Sigma-Aldrich Chemical Company (Sigma Chemical
Co., St. Louis, MO, USA).
BCA Protein Assay kit and complete protease inhibitor
cocktail were purchased from Thermo Fisher Scientific
Inc. (81 Wyman Street, Waltham, MA USA 02451). Rat
MPO sandwich ELISA kit was purchased from Hycult
Biotech (Frontstraat 2a, 5405 PB Uden, The Netherlands).
Rat IL-23 ELISA kit was purchased from 6C USA Inc.
(Ausmausco Pharma, Co., Ltd. China). Glutathione ELISA
kit was procured from Tecan Group Ltd., Männedorf,
Switzerland.
Statistical analysis
SPSS software 20 was used for the statistical analysis.
Data were expressed as means ± S.E.M. Mann–Whitney
U test was used for non-parametric. P values ≤ 0.05 were
regarded as significant.
Results
Effect of curcuma longa (CL) on body weight in acetic
acid-induced inflammatory bowel disease (IBD)
The mean body weight (MBW) in controlled rats (before
IBD) was 249 ± 6.0 g (n = 11). After 4 days of IBD,
the MBW of the untreated rats decreased significantly
(P < 0.05) to 220 ± 7.0 g (n = 10) but recovered by day 7
(263 ± 10.0, n = 11). CL at a dose of 10 mg/kg significantly
(P < 0.05, P < 0.01) increased the MBW to 256 ± 4.0 g
on day 2 after the onset of IBD, (n = 5) and to 295 ± 11.0 g
on day 4 of IBD (n = 6) when compared to untreated IBD
rats (Fig. 1).
The body weight of rats pre-treated with CL by gastric
gavage at doses of 1, 10 and 100 mg/kg per day for 3 days
before the induction of IBD is presented in Fig. 1b. The
MBW of control rats was not significantly affected by
IBD on days 2 and 7. However, a significant reduction in
MBW was seen on day 4 of IBD (222 ± 7.0 g) compared
to control (243 ± 5.0 g). In contrast, the MBW of CL-pre-
treated rats with 10 mg/kg, increased significantly on day
4 after the onset of IBD from 222 ± 7.0 g (untreated rats)
to 251 ± 8.0 g (n = 6)(Fig. 1a1) . CL at doses of 1 and
100 mg/kg/day had no significant effect on MBW at days
2 and 7 of IBD compared to untreated IBD rats.
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Effect of curcuma longa (CL) on mean macroscopic ulcer
and score (MaUS) in acetic acid-induced inflammatory
bowel disease (IBD)
The effect of CL on MaUS in rats when given orally
immediately after the induction of IBD is depicted in
Fig. 2. The mucosa of the colon of untreated rats is
hyperemic and ulcerative. Scoring (Fig. 3) of the lesions
of the hyperemia and ulcer of the colon of acetic acid-
induced IBD rats showed significant (P < 0.001) increase
in MaUS from 0 (control) to 4.2 ± 0.26, 3.9 ± 0.4, and
1.3 ± 0.4 after 2, 4 and days 7, respectively. CL at a dose
of 1 mg/kg, caused a significant decrease in MaUS after
day 7 (0.2 ± 0.02) when compared to untreated groups,
4.2 ± 0.26 (IBD, no CL, n = 6). CL, when administered at
a dose of 100 mg/kg also caused a significant (P < 0.01)
reduction in MaUS after 2 days of IBD from 4.2 ± 0.26
(untreated) to 2.0 ± 0.45. However, CL administered at a
dose of 100 mg/kg had no significant effect on MaUS
after 4 and 7 days of IBD when compared to control
(IBD, no CL).
The effect of CL on hyperemia and ulcer in the mu-
cosa of the colon of control, untreated, and treated rats
is presented in Fig. 2. Note that 10 mg of CL is the most
effective dose in the prevention of hyperemia and ulcer-
ation. IBD caused a significant increase in MaUS from 0
(untreated) to 4.3 ± 0.3 (n = 6), 3.9 ± 0.4, (n = 6) and 1.3
± 0.4 at days 2, 4 and 7, post IBD induction, respect-
ively (Fig. 3a). CL administered at a dose of 1 mg/kg to
IBD rats, resulted in a significant reduction in MaUS from
3.9 ± 0.4, (IBD, no CL) to 1.7 ± 0.6 at day 4. At day 7, a
small but not significant increase was noted in the MaUS.
CL, administered at a dose of 10 mg/kg, significantly
Fig. 1 Figure 1 shows the mean body weight (MBW) of rats treated with Curcuma Longa (CL) before (b) and after (a) IBD. Note that CL at a dose
of 10 mg/kg significantly (P < 0.05) increased the MBW on days 2 and 4 after the onset of IBD, (n = 5–6). *Significance difference between CL-treated
and non IBD control; # Significance difference between CL-treated and IBD control
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reduced MaUS from 4.3 ± 0.3 (IBD, no CL) to 1.2 ± 0.2 at
day 2 and from 3.9 ± 0.4 (IBD, no CL) to 1.3 ± 0.4 at day 4
of IBD. There was a non-significant reduction in MaUS at
day 7 of IBD. CL, when administered at a dose of
100 mg/kg significantly reduced MaUS (1.7 ± 0.4 IBD)
and 0.2 ± 0.17 (IBD) on day 2 and 7, respectively, when
Fig. 2 Figure 2 shows the effect of different doses of Curcuma Longa (CL) on colonic mucosa before (b) or after (a) the onset of acetic acid-induced
IBD. The hyperaemia and ulcers caused by IBD in the colon of these rats were less severe compared to those that were treated with CL after the onset
of IBD. 10 mg/kg of CL appears to have the most beneficial effect (n = 6)
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compared to IBD control at days 2 (4.3 ± 0.3) and 7 (1.3 ±
0.4). On day 4, CL at 100 mg/kg showed no significant
effect on MaUS (Fig. 3b).
Effect of curcuma longa (CL) on the histology and mean
microscopic ulcer score (MiUS) in acetic acid induced-
inflammatory bowel disease (IBD)
Administration of CL reduced lymphatic infiltration in
the colon of rats with acetic acid induced-inflammatory
bowel disease. This is more evident in the group treated
with CL after the induction of IBD (Fig. 4a and b).
The results also show that MiUS was 1.4 ± 0.3 in the
control group (No IBD, no CL). IBD caused a significant
increase in MiUS when compared to saline control. The
MiUS increased from 1.4 ± 0.3 to 3.5 ± 0.1 and 2.7 ± 0.2
at days 2 and 4, respectively. The effect tapered to
almost normal at day 7. CL, at a dose of 1 mg/kg signifi-
cantly reduced the MiUS (2.2 ± 0.2) when compared to
control 3.5 ± 0.14 (IBD) at day 2. On days 4 and 7 of
IBD, CL at 1 mg/kg had no significant effect on MiUS.
CL, at doses of 10 and 100 mg/kg, non-significantly re-
duced MiUS on all days of IBD (Fig. 5).
The effect of CL on MiUS in rats when administered
orally 3 days before the induction of IBD is shown in Fig.
5. IBD caused a significant (P < 0.01, P < 0.001) increase in
MiUS to 3.5 ± 0.2 and 2.6 ± 0.3 on days 2 and 4, respect-
ively compared to a baseline of 1.4 ± 0.3 (control, no
CL, no IBD, n = 6). IBD did not cause any change to the
Fig. 3 Figures 3 shows the effect of orally administered Curcuma Longa (CL) on the macroscopic ulcer score (MaUS) in the colon of rat before (b)
and after (a) the induction of IBD. Note that CL at a dose of 1 and 10 mg/kg, caused a significant (P < 0.05) decrease in MaUS after day 7, when
compared to control. In the pretreated group, CL at a doses of 1, 10 and 100 mg/kg, resulted in a significant (P < 0.001) reduction in MaUS albeit
at different time points. *Significance difference between CL-treated and non IBD control; # Significance difference between CL-treated and IBD
control n = 6
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Fig. 4 (See legend on next page.)
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Fig. 4 Figure 4A shows the effect of Curcuma Longa (CL) on the severity of inflammatory reactions in rats when given orally 30 min after the
induction of IBD for a total of 7 days. The images show that severe lymphatic infiltration (arrow), especially those transcending all layers of the colon is
more prevalent in the colon of untreated IBD rats compared to CL-treated animals. (n = 10). 4A. 1: Non IBD Control, no CL (naive). 4A. 2: 2 Days IBD, (i)
Control, no CL, (ii) 1 mg/kg CL, (iii)10 mg/kg CL, (iv)100 mg/kg CL. 4A. 3: 4-day IBD (i) control, no CL, (ii)1 mg/kg CL, (iii) 10 mg/kg CL, (iv)100 mg/kg CL.
4A. 4: 7-day IBD (i) control, no CL, (ii) 1 mg/kg CL, (iii) 10 mg/kg CL, (iv) 100 mg/kg CL. Figure 4B shows the effect of CL on the microscopy of the colon
of acetic acid-induced IBD rats 3 days before the induction of IBD. IBD caused a significant (P < 0.01) increase in the severity of leucocyte infiltration
(arrow). CL administration at doses of 100 mg/kg did not markedly reduce the degree of leucocyte infiltration. 4B.1(i):Control, no CL, no IBD. 4B.1(ii):
1 mg/kg CL, no IBD, (iii): 10 mg/kg CL, no IBD, 4B.1(iv): 100 mg/kg CL, no IBD. 4B.2(i): no CL + 2 days IBD control; (ii): 1 mg/kg CL, (iii): 10 mg/kg CL +
2 days IBD, (iv): 100 mg/Kg + CL 2 days IBD. 4B.3(i): no CL + 4 days IBD control; (ii):1 mg/kg CL + 4 days IBD, (iii):10 mg/kg CL + 4 days IBD,
(iv):100 mg/kgCL + 4 days IBD. 4B.4(i): no CL + 7 days IBD control; (ii): 1 mg/kg CL + 7 days IBD, (iii): 10 mg/kg CL + 7 days IBD, (iv):100 mg/kgCL + 7 days IBD
Fig. 5 Figure 5 shows the effect of orally administered Curcuma Longa (CL) on microscopic ulcer score (MiUS) in rats before (b) and after (a) the
induction of IBD. Note that CL, at doses of 1, 10 and 100 mg/kg caused a significant (P < 0.001) reduction in MiUS at different time points when
compared to IBD control. *Significance difference between IBD and from Non IBD control; # Significance difference between CL-treated and IBD
control (n = 6)
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MiUS on day 7. However, CL, at doses of 1, 10 and
100 mg/kg caused a significant reduction in MiUS on days
2 and 4 of IBD when compared to IBD control (no CL).
Specifically, MiUS was 2.2 ± 0.2, 0.6 ± 0.08 and 1.5 ± 0.2 at
doses of 1, 10 and 100 mg/kg, respectively on day 2 after
the administration of CL compared to control, untreated
IBD (3.5 ± 0.2). On day 4, MiUS was 0.8 ± 0.1 (n = 6),
0.9 ± 0.08 and 0.9 ± 0.8 after CL administration at doses of
1, 10 and 100 mg/kg, respectively when compared to
untreated group (2.6 ± 0.3).
Effect of curcuma longa (CL) on the mean serum
glutathione (MSGSH) levels in acetic acid-induced
inflammatory bowel disease (IBD)
The effect of CL on MSGSH levels in rats when adminis-
tered orally after the induction of IBD is shown in Fig. 6a.
MSGSH in control (no IBD, no CL) was 33.0 ± 3.0 μM
(n = 6). MSGSH levels increased significantly on days 4
and 7 of IBD. The MSGSH levels were 50.0 ± 1.8 μM
and 45 ± 1.6 μM, respectively. CL significantly increased
MSGSH levels after 2 (44 ± 1.5 μM, 1 mg/kg) and 7 (73 ±
9.0 μM, 10 mg/kg) days of IBD when compared to control.
CL had no effect on MSGSH on day 4 of IBD at all doses
tested. On day 7 of IBD, CL, at a dose of 100 mg/kg,
significantly (P < 0.05) decreased MSGSH levels from
45 ± 1.6 μM (control IBD) to 31 ± 4.0 μM.
Figure 6b shows the effect of CL on MSGSH levels in
rats, when given orally for 3 days before the induction of
IBD. MSGSH in control (CL only, no IBD) was 33.0 ±
3.0 μM. IBD significantly increased MSGSH levels in con-
trol (no IBD, no CL) on days 4 and 7. The MSGSH levels
increased from 33.0 ± 3.0 in control to 51 ± 4.0 μM (day 4)
and 54 ± 3.0 μM (day 7). On day 2 of IBD, the value was
not significantly different from that of positive control
Fig. 6 Figure 6 shows the effect of Curcuma Longa (CL) on mean serum glutathione (MSGSH) levels in rats before (b) and after (a) the induction
of IBD. CL significantly (P < 0.05) increased MSGSH levels after 2 and 7 days of IBD compared to IBD control. *Significance difference between IBD
and from Non IBD control; # Significance difference between CL-treated and IBD control (n = 6)
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group (no IBD, CL only). CL significantly increased
MSGSH levels on days 2 and 4 compared to untreated
control (IBD, no CL). On day 2 of IBD, MSGSH increased
from 35.0 ± 3.0 μM (IBD) to 60 ± 5.0 μM (CL 10 mg/kg).
On day 4 of IBD, CL increased MSGSH levels from 54.0
± 4.0 μM (Control IBD) to 79 ± 9.0 μM (CL 10 mg/kg).
CL, administered at a dose of 1 mg/kg, had no effect on
MSGSH levels compared to control (IBD, no CL). CL, ad-
ministered at a dose of 100 mg/kg significantly reduced
MSGSH levels on all days tested. It thus appear therefore
that very low or high doses of CL decrease on the MSGSH
level, while the average dose of 10 mg increase MSGSH
significantly.
Effect of curcuma longa (CL) on mean colon
myeloperoxidase (MCMPO) levels in acetic acid-induced
inflammatory bowel disease (IBD)
The effect of CL on MCMPO levels in rats administered
orally for 3 days before or 30 min after the induction of
IBD was measured to determine the extent of inflamma-
tion (Fig. 7). MCMPO level in control (No CL, no IBD)
was 74.0 ± 25.0 ng/mg protein. IBD significantly in-
creased MCMPO levels to 9441 ± 510 ng/mg protein in
untreated group (IBD, no CL) after 2 days of IBD. How-
ever, CL significantly reduced MCMPO levels from
9441 ± 510.0 (no CL) to 6157 ± 954 ng/mg of protein,
from 7797 ± 1111 (no CL) to 2374 ± 442 ng/ml of pro-
tein and from 1381 ± 408 (no CL) to 501 ± 94 (n = 5) at
2, 4 and 7 days of IBD, respectively. When CL was
post-administered 30 min after the induction of IBD, CL
significantly reduced the MCMPO levels from 9441 ±
510 ng/ml of protein in untreated group (IBD, no CL)
to 5680 ± 1008 ng/ml of protein, from 7797 ± 1111 to
3660 ± 626 ng/ml of protein and from 1381 ± 408 to
794 ± 302 ng/ml of protein at 2, 4 and 7 days of IBD,
respectively.
Effect of curcuma longa (CL) on mean colon IL 23 levels
in acetic acid-induced inflammatory bowel disease (IBD)
Colonic IL 23, a marker of inflammation, was measured
in to examine the effect of CL after the induction of IBD
(Fig. 8). Mean colonic IL 23 level before IBD in the control
group (no IBD, no CL) was 1.6 ± 0.17 pg/mg of protein.
IBD significantly increased mean colonic IL 23 levels to
3.14 ± 0.37 (IBD, no CL) pg/gm of protein. Pre-treatment
with CL 3 days before IBD significantly reduced mean
colonic IL 23 levels from 3.14 ± 0.37 (no CL) to 2.05 ±
0.09 pg/mg of protein, from 2.10 ± 0.15 to 1.62 ± 0.10 pg/
mg of protein and non-significantly from 2.23 ± 0.44 to
1.81 ± 0.13 (n = 6) pg/mg of protein at 2, 4 and 7 days of
IBD, respectively. Similarly when CL was administered
30 min after the induction of IBD, mean colonic IL
23 was significantly reduced from 3.14 ± 0.37 (no CL)
to 1.99 ± 0.07 pg/mg of protein, from 2.10 ± 0.15 (no CL)
to 1.54 ± 0.16 pg/mg of protein and non-significantly from
2.23 ± 0.44 (no CL) to 1.52 ± 0.14 pg/mg of protein at 2, 4
and 7 days of IBD, respectively.
Discussion
Ulcerative colitis (UC) and Crohn’s disease (CD) are the
two main types of inflammatory bowel disease (IBD).
Patients can be become severely wasted during an acute
attack of the disease [22]. Chronic undernourishment
probably occurs more commonly in CD than in UC
[23, 24]. The rat model of colonic inflammation was
first developed by Morris et al., in 1989 [25] using
Fig. 7 Figure 7 shows the effect of Curcuma Longa (CL) on mean colon myeloperoxidase (MPO) in IBD rat model levels in rats before and after
the induction of IBD. CL significantly (P < 0.05) reduced MPO levels after 2, 4 and 7 days of IBD compared to IBD control. *Significance difference
between IBD and from Non IBD control; # Significance difference between CL-treated and IBD control (n = 6)
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intra-luminal instillation of trinitrobenzene sulfonic acid.
In this study 1 ml of 4 % acetic acid was used, a known in-
ducer of colonic inflammation. The results showed that
IBD decreases body weight in rats, a similar trend seen in
human studies. Several other studies have documented
weight loss of up to 70–80 % of hospitalized patients [26].
According to Mijac et al. [27] weight loss may be an unre-
liable indicator, as it depends on the accuracy of previous
weight measurement, patient’s memory, or water balance
of patients. However, in this study, an animal model of
IBD was used, which did not depend much on such com-
plex parameters. Weight loss and malnutrition in IBD is
multifactorial, and the nutritional status is the result of
complex pathophysiological processes [28, 29]; these in-
clude postprandial pain, diarrhoea or anorexia, malabsorp-
tion and maldigestion due to either the active disease,
protein loss through the bowel and metabolic stress asso-
ciated with both inflammation and steroid therapy [24, 30,
31]. Diarrhoea was observed in all animals tested and
50 % of the IBD rats had blood in their stool, which is in
line with the reports of other investigators [23, 29, 30]. Al-
though IBD is generally treated with antiinflammatory or
immunosuppressive drugs, most of these treatments are
inadequate and consequently, many patients are turning
to alternative treatments such as plant-based remedies.
Food derivatives with plant-based remedies have an added
advantage in that they are relatively nontoxic. Conse-
quently, this study is focused on turmeric, the powdered
rhizome of the medicinal plant, Curcuma longa Linn,
used as a food flavouring and colouring agent in the
Asian diet. It contains curcumin (diferuloylmethane),
a polyphenolic pigment [16]. Curcumin has been shown
to possess a variety of pharmacological effects including
anti-inflammatory activities [17–20]. The results of
the present study clearly indicate that turmeric has a
protective effect on colitis-induced weight loss, a
known parameter of colitis in humans and animals
[21–23, 25–31]. This is the first report of its kind on the
effect of turmeric on experimental colitis in rats using 4 %
acetic acid. The only other similar study was on the anti-
nociceptive effect of CL on acetic acid-induced writhing
movement in mice [32], the effect of its active constituent,
curcumin, on dinitrobenzene-induced experimental colitis
[33] and the effect of curcumin, but not turmeric, on
oxido-inflammatory regulation in a rat model of acetic
acid-induced colitis [34]. Other studies on the effect of
turmeric were done on experimental arthritis and not on
experimental colitis. They observed that turmeric inhib-
ited lipooxygenase and cyclooxygenase pathway and this
could explain its inhibitory action in experimental colitis
in this study [35–37]. Higher doses (100 mg/kg CL)
caused a reduction in weight in this study which is similar
to the observation of Deshpande et al. [38] who used a
dose of 5 % CL for 90 days. Similar observation was made
by Bille et al. [39] who used turmeric oleoresin for 102–
109 days at doses of 60, 296 and 1551 mg/kg. The higher
doses showed a reduction in weight gain.
In order to study the anti-inflammatory effect of CL, we
used 4 % acetic acid, a known inducer of colitis [34, 40–42].
Gross examination of acetic acid-induced colonic ulcer
Macroscopic damage was assessed by using the inflam-
mation/ulcer scoring system of Wallace and Keenan
[21]. This system takes into account the area of inflam-
mation and the presence or absence of ulcers measured
by macroscopic ulcer score (MaUS) which in turn is
based on the semi quantitative scoring system. 6 cm of
colon extending proximally from 2 cm above the anal
margin was removed, split longitudinally, pinned out on
a card, and the macroscopic appearances of the colonic
Fig. 8 Figure 8 shows the effect of Curcuma Longa (CL) on mean colon IL-23 in IBD rat model levels in rats before and after the induction of IBD.
CL significantly (P < 0.05) reduced IL-23 levels after 2 and 4 days of IBD compared to IBD control. *Significance difference between IBD and from
Non IBD control; # Significance difference between CL-treated and IBD control (n = 6)
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mucosa scored as mentioned above. Most of the studies
on CL have used curcumin (the active constituent, also
referred to as curcumin 1 or diferuloylmethane) to test
its anti-inflammatory effect, both in vitro and in vivo
[43–45]. In a pilot, open-labeled, study conducted in
New York, oral curcumin was given to 5 patients with
ulcerative proctitis and 5 patients with Crohn’s disease
(CD), all patients with proctitis and 80 % of patients with
CD showed improvement [46]. Subsequently, other stud-
ies have shown similar anti-inflammatory potential of
curcumin [47, 48]. Since CL also contains other active
constituents namely desmethoxycurcumin (curcumin II),
and bisdesmethoxycurcumin (curcumin III), as well as
volatile oils, sugars, proteins, and resins [43], we decided
to use the raw powdered rhizome of CL to study its effect
in an animal model of inflammation. Our results show
that CL reduced inflammation as measured by the MaUS.
This is consistent with previous report [32, 49], which
were done in adjuvant-induced arthritis (AIA), and carra-
geenan, dextran and formalin induced inflammation.
Light microscopy
In order to get a better insight into the depth of inflam-
mation, we undertook microscopic analysis of the ulcer,
measured as microscopic ulcer score or MiUS. The
microscopic analysis was based on the scoring system of
Neurath et al. [5]. Randomly distributed full thickness
biopsy specimens were used for this experiment. The
results show that 4 % acetic acid caused a substantial
degree of inflammation and tissue injury in the rat colon
as demonstrated by the MiUS which in turn corresponds
to an infiltration of the colon with leukocytes cells.
Although macroscopic examination showed no evidence
of any injury in control, microscopic observation showed
some low level infiltration of the colon (no IBD, no CL).
This is not unusual and commonly used bowel prepara-
tions can produce histological abnormalities of the colo-
rectal mucosa [50, 51]. These might include surface
erosions and leucocyte infiltration of the surface epithe-
lium (aphthoid ulcers/lesions) and sometimes focal
active cryptitis (FAC) as well as leucocyte infiltration of
the subepithelial lamina propria [50, 52, 53]. The induc-
tion of IBD by 4 % acetic acid caused a substantial in-
crease in transmural leukocytes infiltration, loss of goblet
cells, high vascular density and thickening of the colonic
wall. This is line with similar observation [34, 40, 41] done
on acetic-acid- and 2,4,6-trinitrobenzene sulphonic
acid–induced colitis in mice and rats. CL caused a signifi-
cant reduction in the MiUS as demonstrated by reduced
infiltration by leucocytes. This effect of CL in experimen-
tal acetic acid-colitis is unique in that others have shown
anti-inflammatory and anti-oxidant effects of CL on
carrageenan, dextran and formalin and adjuvant-induced
arthritis, respectively [32, 49].
Anti-oxidant effect of curcuma longa Linn
CL has been shown to have anti-oxidant and anti-
inflammatory properties [32, 49] and curcumin, a yellow
colouring agent extracted from CL, has also been shown
to have anti-inflammatory and anti-oxidant activity
[18–20]. There is a growing body of evidence implicating
reactive oxygen metabolites as important mediators of
inflammation-induced mucosal injury associated with IBD
[49, 50]. Phagocytic leukocytes are most probably the
source of these oxidants which are known to be present in
large numbers in the inflamed mucosa and are known to
produce large amounts of reactive oxygen species (ROS)
in response to inflammation [54]. Because the gut mucosa
contain relatively small amounts of antioxidant enzymes
such as superoxide dismutase (SOD), catalase, glutathione
(GSH) peroxidase, it is possible that it may be over-
whelmed during times of active inflammation which could
result in intestinal injury [54]. An imbalance between
increased reactive oxygen species levels and de-
creased antioxidant defenses occurs in CD patients.
Therefore, we undertook this study to determine
whether serum levels of GSH is affected in acetic
acid-induced colitis in rats. Our study showed that
IBD increased serum GSH levels in control (no CL),
which is in contrast to other who observed a reduc-
tion in GSH levels [41, 55, 56]. This is probably a
compensatory mechanism to counter the inflammatory
responses. Administration of CL significantly increased
serum GSH levels which were higher and above the in-
crease observed in control IBD (no CL) which is the first
report of its kind in acetic acid-induced IBD. Other re-
ports [49, 50] were on carrageen, dextran, formalin and
adjuvant-induced arthritis.
Inflammatory markers
Thus, CL acts as a protective mechanism counteracting
the inflammation seen in our study.
Because of the presence of neutrophils in the mucosa
and submucosa of the colon, we undertook to measure
the colon myeloperoxidase (MPO) since it is extensively
used as a biochemical marker for granulocyte (mainly
neutrophil) infiltration into gastrointestinal tissues [25].
MPO is a glycosylated hemoprotein enzyme found in
granules of human neutrophils and monocytes [57]. It is
an important enzyme used during phagocytic lysis of
engulfed foreign particles which takes part in the defense
of the organism through production of hypochlorous
acid (HOCl), a potent oxidant and an endogenous halide
during phagocytosis, thereby contributing to the overall
microbicidal and cytotoxic function of the polymorpho-
nuclear leukocytes (PMN). MPO also modulates inflam-
mation by generating ROS and thus contribute to the
inflammation, which was evident in our study [58–60].
In this study, CL inhibited colonic MPO levels which
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indirectly reduces autooxidants and thus contribute to
its overall anti-inflammatory properties.
The demonstration of the association of IL-23 pathway
in multiple chronic inflammatory disorders, including in-
flammatory bowel disease (IBD) prompted us to measure
the colonic IL 23 levels. Our results clearly showed that CL
has a protective action against inflammation judging from
its inhibitory actions on colonic IL 23. Evidence for the im-
portance of IL-23 pathway in IBD has come from mouse
models of IBD, in which IL-23 deficiency or blockade pro-
tects not only the mice from the disease [7, 8], but human
IBD as well [9–11]. IL 23 does not stimulate interferon-γ
(INF- γ) but acts on memory B and T cells and is thought
to enhance CD4+ T cells that produce IL 17 [7].
Treatment of C. longa before or after the onset of
inflammatory bowel disease
The beneficial effects of C. longa on both macro- and
macroscopic ulcer scoring, antioxidant pool, and level of
inflammatory markers appear to be more conspicuous
when administered before the onset of IBD. The differ-
ences may be due to the fact that a significant tissue
damage may already have been done when C. longa is
administered after the induction of IBD. The C. longa
given may therefore not be able to repair the damage
that has already been done to the colonic mucosa. In
contrast, C. longa, when given before the onset of IBD is
able to increase the tissue level of GSH, an endogenous
antioxidant that is capable of reducing the level of oxida-
tive stress generated by acetic acid. This is evident from
the fact that the level of inflammatory markers is signifi-
cantly higher after the administration of IBD. It thus ap-
pears that increased C. longa-induced GSH plays a part
in the reduction of the deleterious effect of IBD and es-
pecially when it is given before the onset of the disease.
Conclusion
In conclusion CL administration, either before or after
the induction of IBD displays potent anti-inflammatory
effects, as shown by the recovery in MBW, MaUS and
MiUS and and inhibition of MPO and IL 23. All of these
may suggest the possibility of developing C. longa as a
safe and potent anti-inflammatory and antioxidant sub-
stance in the fight against IBD. 10 mg appears to be the
ideal dose as very low (1 mg) or high (100 mg) do pro-
duce inconsistent outcomes. A possible reason for the
inconsistencies with the very low or high doses is that
the concentration of the active ingredients may be un-
evenly dispersed within the powder and leading to unequal
amount of absorbed phytochemical.
Limitations of the study
C. longa was observed to be beneficial at some doses while
un-effective in others. The reason for this observation
may be due to the fact that a powdered form of C. longa
was used. A probable cause of this observation could be
an uneven distribution of the active ingredients of C. longa
powder. In addition, the absorption of C. longa after oral
administration may not be even after all.
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